OVERSEA CHINESE BANKING Corp Ltd Purchases 9,557 Shares of Illumina, Inc. (NASDAQ:ILMN)

OVERSEA CHINESE BANKING Corp Ltd raised its position in Illumina, Inc. (NASDAQ:ILMNFree Report) by 41.2% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 32,768 shares of the life sciences company’s stock after buying an additional 9,557 shares during the quarter. OVERSEA CHINESE BANKING Corp Ltd’s holdings in Illumina were worth $4,563,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Annis Gardner Whiting Capital Advisors LLC acquired a new stake in shares of Illumina in the 3rd quarter valued at approximately $30,000. State of Wyoming acquired a new stake in shares of Illumina in the 2nd quarter valued at approximately $32,000. VisionPoint Advisory Group LLC boosted its stake in shares of Illumina by 344.6% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company’s stock valued at $34,000 after purchasing an additional 193 shares in the last quarter. Riverview Trust Co boosted its stake in shares of Illumina by 203.5% in the 3rd quarter. Riverview Trust Co now owns 261 shares of the life sciences company’s stock valued at $36,000 after purchasing an additional 175 shares in the last quarter. Finally, Wetzel Investment Advisors Inc. acquired a new stake in shares of Illumina in the 4th quarter valued at approximately $37,000. 89.42% of the stock is owned by institutional investors.

Insider Activity at Illumina

In other news, CEO Jacob Thaysen purchased 7,330 shares of the business’s stock in a transaction on Thursday, February 22nd. The shares were acquired at an average price of $135.29 per share, for a total transaction of $991,675.70. Following the completion of the acquisition, the chief executive officer now owns 14,861 shares in the company, valued at $2,010,544.69. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.17% of the stock is currently owned by corporate insiders.

Illumina Trading Up 0.6 %

Shares of ILMN stock traded up $0.74 during trading hours on Friday, hitting $117.43. 1,418,214 shares of the company were exchanged, compared to its average volume of 1,428,645. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.29 and a current ratio of 1.66. Illumina, Inc. has a fifty-two week low of $89.00 and a fifty-two week high of $229.58. The company has a 50 day simple moving average of $133.37 and a two-hundred day simple moving average of $127.89. The firm has a market cap of $18.70 billion, a P/E ratio of -16.00 and a beta of 1.19.

Illumina (NASDAQ:ILMNGet Free Report) last posted its quarterly earnings results on Thursday, February 8th. The life sciences company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. The business had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.09 billion. During the same period last year, the company posted $0.14 earnings per share. The business’s quarterly revenue was up 3.6% on a year-over-year basis. Equities analysts anticipate that Illumina, Inc. will post 0.91 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on ILMN shares. HSBC downgraded shares of Illumina from a “buy” rating to a “hold” rating in a research note on Tuesday, January 16th. Royal Bank of Canada reiterated an “outperform” rating and set a $253.00 target price on shares of Illumina in a research report on Tuesday, April 9th. Barclays lifted their target price on shares of Illumina from $85.00 to $100.00 and gave the stock an “underweight” rating in a research report on Wednesday, April 10th. Stephens reiterated an “overweight” rating and set a $170.00 target price on shares of Illumina in a research report on Wednesday, April 10th. Finally, TD Cowen downgraded shares of Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 target price on the stock. in a research report on Thursday, January 4th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $167.70.

Read Our Latest Analysis on ILMN

Illumina Company Profile

(Free Report)

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Featured Stories

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMNFree Report).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.